← All trials
NCT02203253
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2014
- Primary completion
- Jul 1, 2016
- Completion date
- Aug 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 642
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- China Medical UniversityLead sponsor
- China Medical UniversityReponsible party - principal investigator
- Shengjing HospitalCollaborator
- Liaoyang Central HospitalCollaborator
- Third People's hospital LiaoyangCollaborator
- Petrochemical General Hospital of Liaoyang cityCollaborator
- Anshan Tumor HospitalCollaborator
- Dalian Medical UniversityCollaborator
- Liaoning Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- China Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.